Back to Search
Start Over
A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome
- Source :
- New England Journal of Medicine. 323:1009-1014
- Publication Year :
- 1990
- Publisher :
- Massachusetts Medical Society, 1990.
-
Abstract
- Background. The initially tested dose of zidovudine for the treatment of patients with advanced disease caused by the human immunodeficiency virus type 1 (HIV) was 1500 mg. Although this dose is effective, it is associated with substantial toxicity. Methods. To evaluate the efficacy and safety of a reduced dose, we conducted a randomized controlled trial in 524 subjects who had had a first episode of Pneumocystis carinii pneumonia. The subjects were assigned to receive zidovudine in either a dose of 250 mg taken orally every four hours (the standard-treatment group, n = 262) or a dose of 200 mg taken orally every four hours for four weeks and thereafter 100 mg taken every four hours (the low-dose group, n = 262). Results. The median length of follow-up was 25.6 months. At 18 months the estimated survival rates were 52 percent for the standard-treatment group and 63 percent for the low-dose group (P = 0.012 by the log-rank test). At 24 months the estimated survival rates were 27 percent for the st...
- Subjects :
- First episode
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
General Medicine
Neutropenia
medicine.disease
Surgery
law.invention
Zidovudine
Randomized controlled trial
law
Internal medicine
Toxicity
medicine
Every Four Hours
Adverse effect
business
medicine.drug
Subjects
Details
- ISSN :
- 15334406 and 00284793
- Volume :
- 323
- Database :
- OpenAIRE
- Journal :
- New England Journal of Medicine
- Accession number :
- edsair.doi...........624af636d3bc73626c2dc5f53c9d47bc